Paris, November 24, 2025
Eurazeo is joining Excelya, a European clinical research services provider, as a lead investor alongside its management team to support the Group in continuing its development and pursuing external growth ambitions.
The investment, led by the Flex Financing team, marks a new milestone for Excelya, which now benefits from the backing of a long-term investor recognised for its expertise in the healthcare sector.
Eurazeo’s investment aims to accelerate the Group’s growth while supporting a management transition marked by Frédéric Paqueville’s decision to step back from his operational role in favour of key managers working alongside François Moisson.
Through this transaction, Excelya seeks to accelerate its European expansion, notably through targeted external growth. The Group aspires to become the European leader in clinical research, positioning itself as the preferred partner for mid-sized European pharmaceutical companies, thereby addressing the challenges of healthcare sovereignty in Europe.
Excelya’s ambition is also driven by continuous investments in innovation, particularly in artificial intelligence and automation solutions, aimed at optimising the conduct of clinical trials, improving data quality, and enhancing operational efficiency for its clients and patients
Founded in 2014 by François Moisson and Frédéric Paqueville, Excelya has established itself in Europe as a trusted partner for pharmaceutical companies and healthcare players, thanks to a comprehensive range of services covering all stages of clinical trials. To date, Excelya’s teams have contributed to more than 550 clinical studies across a wide range of therapeutic areas. The Group has recognised expertise in oncology, haematology, rare and paediatric diseases, infectious diseases, inflammation and immunotherapy, pain, central nervous system disorders, as well as late-phase trials and real-world evidence (RWE).
This transaction is fully aligned with Eurazeo’s strategy of supporting high-potential European companies that are innovative and committed to transforming their sector, as well as with the Flex Financing team’s approach of providing managerial or family-owned groups with tailor-made financing solutions combining equity and quasi-equity, while ensuring management retains capital control.
Excelya is thus committing alongside Eurazeo to combining financial performance with impact, aiming to improve employee engagement and satisfaction and to reduce its carbon emissions – two strategic priorities for the Group.
The financing of the transaction is supplemented by bank debt coordinated by Banque Populaire Val de France and Banque Populaire Rives de Paris, with the participation of BNP Paribas, Crédit Lyonnais, and Société Générale.
Valérie Ducourty, Managing Director Eurazeo – Flex Financing, declares :
“We are delighted to support Excelya, whose trajectory and values fully resonate with our responsible investment strategy, in which healthcare innovation is a major component. This investment in Excelya reflects our commitment to supporting European champions in high-impact sectors,”
François Moisson, CEO of Excelya, adds :
“We are proud to take this new step with Eurazeo, which immediately embraced our Purpose: ‘Contributing to humanity’s well-being by developing new ways to heal.’ This mission drives our ambition to become the European leader in clinical development while offering the best employee experience. Together, we will accelerate our growth, strengthen our presence in Europe, and continue to innovate to address the major challenges of clinical research.”
